Tesamorelin Before and After

What “before and after” actually means with tesamorelin

The phrase “before and after” sets an expectation: two photos, an obvious visible change, a transformation you can point at. Tesamorelin doesn’t fit that frame cleanly, and understanding why is the whole point of this page.

Tesamorelin (marketed as EGRIFTA WR, which replaced EGRIFTA SV in 2025) is a synthetic analog of growth hormone-releasing hormone. It is FDA-approved for one specific use: reducing excess visceral abdominal fat in adults living with HIV who have lipodystrophy. Its mechanism is targeted. It nudges the pituitary to release more of the body’s own growth hormone, which in turn shifts metabolism toward burning visceral adipose tissue — the deep fat packed around the internal organs, not the pinchable fat just under the skin.

That distinction is the key to every realistic expectation. The most reliable “before and after” with tesamorelin is the one a CT scan captures: a reduction in the fat you can’t see, sitting deep in the abdomen. A photo may or may not reflect it.

Note: This page is about realistic expectations, not a transformation gallery. We don’t reproduce or endorse before-and-after photos, many of which involve unverified products and uncontrolled variables.

What the clinical evidence shows changed

The strongest data come from two pivotal Phase III trials and their pooled analyses. The numbers are specific and worth knowing, because they anchor expectations far better than any anecdote.

Across roughly 800 participants, tesamorelin reduced visceral adipose tissue by approximately 15% versus placebo at 26 weeks — a statistically robust effect. A later meta-analysis put the absolute reduction at around 28 cm² of visceral fat on cross-sectional imaging. Alongside that, trials recorded a modest reduction in waist circumference (on the order of 1-2 cm), a small drop in trunk fat, improvements in fasting triglycerides, and a measurable increase in lean body mass.

Those are real, consistent changes. But notice what they describe: an internal redistribution, a slightly trimmer waist measurement, better blood lipids. They do not describe a sweeping change in overall body weight or a dramatic silhouette shift.

What did NOT change — and why that matters for photos

This is where most “before and after” expectations go wrong.

The same trials that found a 15% visceral fat reduction found no significant change in BMI and no clinically significant change in subcutaneous fat — the fat layer just under the skin that actually shapes how a stomach looks in a photo. Tesamorelin works on the deep compartment and largely leaves the surface layer alone.

The practical consequence: a person can lose a meaningful amount of visceral fat, improve their metabolic markers, and look only modestly different in a mirror or photograph. Someone with a lot of subcutaneous fat over the abdomen may see very little visible change even with a “successful” internal result. This is not a failure of the drug; it’s what the drug does. A flatter, less distended-looking abdomen is plausible over months — a flat-stomach transformation is not the documented outcome.

For HIV-associated lipodystrophy specifically, even a non-dramatic visual change can matter a great deal, because the condition involves visible, distressing central fat accumulation. Trials did record improvements in body-image distress scores. But “felt better about my body” is a different claim from “dramatic visible transformation,” and the evidence supports the former more than the latter.

The timeframe behind any “after”

There is no quick before-and-after with tesamorelin. The trial measurements that everyone cites were taken at 26 weeks — roughly six months — with benefits maintained through 52 weeks in the extension phases for those who continued treatment.

That means any honest “after” is a months-long, gradual accrual, not a weeks-long flip. If you’re imagining a sequence of monthly photos, the early frames realistically show very little, and the differences (where they appear at all) emerge slowly across the back half of the first year. For a fuller chronology of what tends to happen when, see our tesamorelin results timeline.

The part most before-and-after content leaves out: it reverses

Here is the single most important caveat, and it’s well documented across the trial literature: when tesamorelin is discontinued, visceral fat re-accumulates.

The “after” is conditional. It holds while treatment continues and erodes when it stops. This reframes the whole before-and-after concept. With tesamorelin you’re not buying a permanent transformation you can stop paying for; you’re maintaining an ongoing therapeutic effect. That has real implications for cost, commitment, and whether the trade-off makes sense for a given person — see tesamorelin cost for the financial side of “ongoing” versus “one-time.”

Why individual results vary so widely

Even within the approved indication, response is not uniform. The label itself advises reconsidering continued treatment in patients who don’t show a clear visceral-fat response. Several factors drive that variation:

• Starting point. Someone with a large visceral fat burden has more room to show measurable change than someone with little to begin with.
• The subcutaneous-fat factor. As above, surface fat largely masks or reveals the internal change in any photo.
• Adherence and duration. The effect builds over months and depends on consistent use.
• Individual hormonal response. Growth hormone and IGF-1 responses differ between people.
• Everything around the drug. Diet, training, sleep, and overall health shape body composition far more visibly than tesamorelin alone.

This is why two people on the same regimen can have genuinely different “afters” — and why a single impressive photo tells you almost nothing about what to expect.

A word on the photos you’ll find online

A large share of circulating tesamorelin before-and-after images sit outside any clinical context. They often involve gray-market “research” vials of unknown concentration and purity, combined with concurrent training, dieting, other compounds, and the usual photographic variables of lighting, posture, pump, and hydration. None of that is controlled, verified, or measurable. Treating those images as evidence of what tesamorelin “does” mixes up the drug with everything else in the frame.

If you’re evaluating tesamorelin, the trial data — modest, specific, reversible — is a far more honest guide than a gallery. And if you’re weighing access, the only legitimate routes run through a licensed prescriber; see how to get tesamorelin in the US and the documented side effects before forming a picture.

How to judge a “before and after” honestly

If you want to evaluate change in a way that actually means something, the trial framework is a useful model. Clinicians don’t rely on photos; they track visceral fat on imaging, waist circumference with a tape measure under standardized conditions, and metabolic markers like triglycerides and IGF-1 on bloodwork. Those measures are reproducible and hard to fake. A photo is none of those things.

This matters for off-label and non-HIV contexts too, where tesamorelin is sometimes discussed for general abdominal fat or longevity. The evidence base there is far thinner than for the approved indication, and any “before and after” claim from that setting carries even less weight — fewer controlled measurements, more confounding variables, and no regulatory backing for the use. The approved label is deliberately narrow precisely because that’s where the data is strong. Treat results claims for other uses with proportional skepticism, and read tesamorelin reviews with the same lens: what’s being measured, over what time, under whose supervision.

The realistic bottom line

A truthful tesamorelin “before and after” reads like this: over about six months of consistent, prescribed use, an adult with HIV-associated lipodystrophy can expect a roughly 15% reduction in deep visceral fat, a small waist-measurement change, improved triglycerides, and modestly improved body image — an effect that holds only while treatment continues. What it is not is a dramatic, permanent, visible body transformation, a weight-loss result, or anything captured reliably in a single pair of photos. Set expectations to the scan, not the mirror, and the picture stays honest. For the mechanism and broader value, see tesamorelin benefits and what tesamorelin is.